Roflumilast vs. Liraglutide and Metformin Compared for Weight Loss in Obese PCOS Women

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder in women, characterized by hormonal imbalances, ovulatory dysfunction, and significant metabolic comorbidities, including insulin resistance and obesity. Current therapeutic approaches often focus on symptom management, with metformin commonly used to improve insulin sensitivity and menstrual regularity. However, effective and sustained weight reduction remains a critical unmet need for many obese PCOS patients, contributing to long-term health risks. GLP-1 receptor agonists like liraglutide have demonstrated efficacy in weight management and metabolic improvement in various populations, while phosphodiesterase-4 (PDE-4) inhibitors such as roflumilast are being investigated for their anti-inflammatory and metabolic modulating properties, offering a potential novel pathway to address PCOS-related obesity.

This study was designed to evaluate the comparative effectiveness of three monotherapy treatments in obese women diagnosed with polycystic ovary syndrome (PCOS) who had not received prior treatment. The primary objective was to assess whether the PDE-4 inhibitor roflumilast demonstrated superior efficacy in weight reduction compared to the GLP-1 agonist liraglutide or metformin. While specific details on dosing, administration route, frequency, or study duration are not provided in the abstract, the design implies a randomized, controlled comparison of these three distinct pharmacological interventions. The primary endpoint for this investigation was anticipated to be the magnitude of change in body weight across the treatment arms.